ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0502

Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis

Sara Rahmati1, Fatima Abji1, Proton Rahman2 and Vinod Chandran3, 1University Health Network, Toronto, ON, Canada, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Bioinformatics, Biomarkers, proteomics, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Psoriatic Arthritis (0499–0503)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better outcomes. Since almost 90% of patients develop PsA either simultaneously or after the onset of cutaneous psoriasis, careful evaluation of psoriasis patients may increase early identification of PsA. Although several candidate protein markers have been demonstrated to be associated with PsA, individually the power to discriminate between PsA and psoriasis without PsA (PsC) is poor. Here, we have developed a computational approach to identify 9 alternative signatures by combining clinical and protein markers to improve discrimination between PsA and PsC.

Methods: Serum samples were obtained from 192 PsA and 191 PsC patients (Table 1). Sixteen protein markers identified in previous studies were assayed in serum samples using ELISA and combined with four clinical features associated with PsA and easily identified by non-rheumatologists (Table 1). To classify patients, we used Support Vector Machines (SVM). To identify the best performing signatures (markers and classifier parameters) we used a three-layer approach. In the first two layers, for training and testing classifiers, we used data only from patients with polyarticular PsA (tender or swollen joint count > 4), while in the third layer, we used all PsA samples. Evaluation of signatures was done using 10-fold cross-validation. First, using a greedy algorithm we identified 41 signatures with accuracy above 75%. Next, we identified 9 signatures using four different measures based on frequency of features and AUCs of these 41 signatures. In the third layer, we used three sample sets for training and testing 2700 classifiers: all samples, only oligoarticular (tender or swollen joint count ≤ 4) PsA, and only polyarticular PsA. All 9 classifiers were trained and tested on similar training and testing sets. Finally, we prioritized the 9 signatures based on their AUC ranks (Table 2).

Results: Demographics and clinical features of patients are provided in Table 1. We propose 9 signatures as alternative signatures to use for distinguishing PsA from PsC, depending on available data, all of which share four features: nail psoriasis, LEP, CRP, and SOST (Table 2). Importantly, the lowest ranked signatures were those without SPP1, suggesting its importance in classifying patients. Our top feature set (Table 2) obtained AUC of up-to 90% on polyarticular samples (median 75%).  Performance slightly dropped when we considered all samples, or only oligoarticular samples (Figure 1). Median AUC of 68% (max AUC = 86%) for distinguishing oligoarticular PsA cases from PsC is significant considering high similarity between patients of these two groups.

Conclusion: Integration of clinical and biomarker data through machine learning improves discrimination of PsA from PsC patients. Nail psoriasis and CRP followed by SPP1 are the most important features influencing performance of classifiers. Nail psoriasis, CRP, DEFA1, LEP, SOST, SPP1, TFCP2_CPII, TNFRSF11B provided best discrimination between PsA and PsC and needs further validation.

Table 1. Clinical and demographic information about samples

Table 2. 9 identified feature sets sorted based on their score (the higher the score, the better) We used same combinations of samples to train and test all 9 classifiers. To obtain the scores, for each training and testing set, we ranked all of the 9 classifiers from 1 to 9 (1 for the lowest and 9 for the highest AUC). Next, for each signature, we multiplied its frequency at each rank by the rank. The scores in this table are the sum up of these 9 values for each of the three categories of samples.

Figure 1. Distribution of AUC of SVMs (y-axis) using each of the 9 identified signatures (listed above each panel) as their feature sets. Each classifier was trained and tested 100 times using three different samples sets: all PsC samples and 1) only polyarticular samples; 2) only oligoarticular samples; 3) all samples. Three boxplots in each panel shows AUC distribution relevant to these three sample sets. For all 9 classifiers, similar training and testing sets were used, making their performance comparable. While all 9 signatures are among high performing signatures, the top left panel was the highest rank in our list.


Disclosure: S. Rahmati, None; F. Abji, None; P. Rahman, AbbVie, 5, 8, Amgen, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Abbott, 8, Centacor, 8, Merck, 8, Bristol Myers Squibb, 5, 8, Roche, 5; V. Chandran, Abbvie, 2, 5, Amgen, 2, 5, Celgene, 2, 5, Eli Lilly, 5, Eli Lilly, 3, Janssen, 8, Novartis, 5, Pfizer, 5, UCB, 5.

To cite this abstract in AMA style:

Rahmati S, Abji F, Rahman P, Chandran V. Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/integration-of-clinical-and-protein-markers-through-machine-learning-to-distinguish-patients-with-psoriasis-arthritis-from-those-with-psoriasis-without-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/integration-of-clinical-and-protein-markers-through-machine-learning-to-distinguish-patients-with-psoriasis-arthritis-from-those-with-psoriasis-without-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology